Management ChangeJun 25, 2026, 08:07 AM
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
AI Summary
Candel Therapeutics, Inc. announced the appointment of Mark Sims as Chief Commercial Officer, effective July 6, 2026. Mr. Sims will lead the commercial strategy and launch readiness for aglatimagene besadenovec (CAN-2409) in intermediate- to high-risk localized prostate cancer. This appointment supports the planned BLA submission in Q4 2026 and a potential 2027 launch, targeting approximately 65,000 US patients annually. Mr. Sims brings over 25 years of oncology commercial experience to the role.
Key Highlights
- Mark Sims appointed Chief Commercial Officer, effective July 6, 2026.
- Mr. Sims will lead commercial strategy for aglatimagene besadenovec (CAN-2409).
- Planned Biologics License Application (BLA) submission for aglatimagene in Q4 2026.
- Potential commercial launch of aglatimagene besadenovec in 2027.
- Target market: ~65,000 US patients annually for localized prostate cancer.
- Mr. Sims has over 25 years of oncology commercial leadership experience.
Price Impact
More from CADL